FilingReader Intelligence
Xuerong Bio faces delisting risk amid financial strain
April 21, 2025 at 12:13 PM UTC•By FilingReader AI
Shanghai Xuerong Bio-Technology (SZSE:300511) is grappling with significant financial and ownership restructuring, raising concerns about its future. A recent on-site inspection by SDIC Securities highlights governance and internal control effectiveness but also flags a projected loss of between CNY 435 million and CNY 650 million for 2024, attributed to weak market conditions and decreased production capacity.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Shanghai Xuerong Biotechnology Co., Ltd.'s indicative announcement on the expected triggering of redemption conditions for Xuerong convertible bondsApril 14, 2025 at 11:19 AM UTC
Announcement of Shanghai Xuerong Biotechnology Co., Ltd. on applying for a loan from a bank and providing mortgage guaranteeApril 15, 2025 at 12:07 PM UTC
Shanghai Xuerong Biotechnology Co., Ltd.'s announcement on the signing of the "Supplementary Agreement to the Framework Agreement on Change of Control and the Share Transfer Agreement" by the controlling shareholderApril 17, 2025 at 08:49 AM UTC
News Alerts
Get instant email alerts when Shanghai Xuerong Bio-Technology publishes news
Free account required • Unsubscribe anytime